Literature DB >> 22652908

MAPK phosphorylation of connexin 43 promotes binding of cyclin E and smooth muscle cell proliferation.

Scott R Johnstone1, Brett M Kroncke, Adam C Straub, Angela K Best, Clarence A Dunn, Leslie A Mitchell, Yelena Peskova, Robert K Nakamoto, Michael Koval, Cecilia W Lo, Paul D Lampe, Linda Columbus, Brant E Isakson.   

Abstract

RATIONALE: Dedifferentiation of vascular smooth muscle cells (VSMC) leading to a proliferative cell phenotype significantly contributes to the development of atherosclerosis. Mitogen-activated protein kinase (MAPK) phosphorylation of proteins including connexin 43 (Cx43) has been associated with VSMC proliferation in atherosclerosis.
OBJECTIVE: To investigate whether MAPK phosphorylation of Cx43 is directly involved in VSMC proliferation. METHODS AND
RESULTS: We show in vivo that MAPK-phosphorylated Cx43 forms complexes with the cell cycle control proteins cyclin E and cyclin-dependent kinase 2 (CDK2) in carotids of apolipoprotein-E receptor null (ApoE(-/-)) mice and in C57Bl/6 mice treated with platelet-derived growth factor-BB (PDGF). We tested the involvement of Cx43 MAPK phosphorylation in vitro using constructs for full-length Cx43 (Cx43) or the Cx43 C-terminus (Cx43(CT)) and produced null phosphorylation Ser>Ala (Cx43(MK4A)/Cx43(CTMK4A)) and phospho-mimetic Ser>Asp (Cx43(MK4D)/Cx43(CTMK4D)) mutations. Coimmunoprecipitation studies in primary VSMC isolated from Cx43 wild-type (Cx43(+/+)) and Cx43 null (Cx43(-/-)) mice and analytic size exclusion studies of purified proteins identify that interactions between cyclin E and Cx43 requires Cx43 MAPK phosphorylation. We further demonstrate that Cx43 MAPK phosphorylation is required for PDGF-mediated VSMC proliferation. Finally, using a novel knock-in mouse containing Cx43-MK4A mutation, we show in vivo that interactions between Cx43 and cyclin E are lost and VSMC proliferation does not occur after treatment of carotids with PDGF and that neointima formation is significantly reduced in carotids after injury.
CONCLUSIONS: We identify MAPK-phosphorylated Cx43 as a novel interacting partner of cyclin E in VSMC and show that this interaction is critical for VSMC proliferation. This novel interaction may be important in the development of atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652908      PMCID: PMC3405546          DOI: 10.1161/CIRCRESAHA.112.272302

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  57 in total

Review 1.  Gap junctions and connexin-interacting proteins.

Authors:  Ben N G Giepmans
Journal:  Cardiovasc Res       Date:  2004-05-01       Impact factor: 10.787

2.  Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells.

Authors:  Christos E Chadjichristos; Sandrine Morel; Jean-Paul Derouette; Esther Sutter; Isabelle Roth; Anne C Brisset; Marie-Luce Bochaton-Piallat; Brenda R Kwak
Journal:  Circ Res       Date:  2008-01-31       Impact factor: 17.367

3.  Oxidized LDL affects smooth muscle cell growth through MAPK-mediated actions on nuclear protein import.

Authors:  Mirna N Chahine; David P Blackwood; Elena Dibrov; Melanie N Richard; Grant N Pierce
Journal:  J Mol Cell Cardiol       Date:  2008-10-28       Impact factor: 5.000

4.  Neointima formation in a restenosis model is suppressed in midkine-deficient mice.

Authors:  M Horiba; K Kadomatsu; E Nakamura; H Muramatsu; S Ikematsu; S Sakuma; K Hayashi; Y Yuzawa; S Matsuo; M Kuzuya; T Kaname; M Hirai; H Saito; T Muramatsu
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

5.  Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells.

Authors:  K Tanaka; K Hayashi; T Shingu; Y Kuga; K Nomura; G Kajiyama
Journal:  Cardiovasc Drugs Ther       Date:  1998-03       Impact factor: 3.727

6.  Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits.

Authors:  M E Rosenfeld; R Ross
Journal:  Arteriosclerosis       Date:  1990 Sep-Oct

7.  Disruption of gap junctional communication by the platelet-derived growth factor is mediated via multiple signaling pathways.

Authors:  M Z Hossain; A B Jagdale; P Ao; A Kazlauskas; A L Boynton
Journal:  J Biol Chem       Date:  1999-04-09       Impact factor: 5.157

8.  Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells.

Authors:  Alexandra Gellhaus; Xuesen Dong; Sven Propson; Karen Maass; Ludger Klein-Hitpass; Mark Kibschull; Otto Traub; Klaus Willecke; Bernard Perbal; Stephen J Lye; Elke Winterhager
Journal:  J Biol Chem       Date:  2004-06-04       Impact factor: 5.157

9.  Luteinizing hormone causes MAP kinase-dependent phosphorylation and closure of connexin 43 gap junctions in mouse ovarian follicles: one of two paths to meiotic resumption.

Authors:  Rachael P Norris; Marina Freudzon; Lisa M Mehlmann; Ann E Cowan; Alexander M Simon; David L Paul; Paul D Lampe; Laurinda A Jaffe
Journal:  Development       Date:  2008-10       Impact factor: 6.868

10.  The gap junction-independent tumor-suppressing effect of connexin 43.

Authors:  You-Wei Zhang; Makoto Kaneda; Ikuo Morita
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

View more
  42 in total

1.  Phosphorylation of connexin 43 at MAPK, PKC or CK1 sites each distinctly alter the kinetics of epidermal wound repair.

Authors:  Kristin J Lastwika; Clarence A Dunn; Joell L Solan; Paul D Lampe
Journal:  J Cell Sci       Date:  2019-09-23       Impact factor: 5.285

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 3.  Posttranslational modifications in connexins and pannexins.

Authors:  Scott R Johnstone; Marie Billaud; Alexander W Lohman; Evan P Taddeo; Brant E Isakson
Journal:  J Membr Biol       Date:  2012-06-28       Impact factor: 1.843

Review 4.  Specific Cx43 phosphorylation events regulate gap junction turnover in vivo.

Authors:  Joell L Solan; Paul D Lampe
Journal:  FEBS Lett       Date:  2014-02-04       Impact factor: 4.124

Review 5.  Regulation of cellular communication by signaling microdomains in the blood vessel wall.

Authors:  Marie Billaud; Alexander W Lohman; Scott R Johnstone; Lauren A Biwer; Stephanie Mutchler; Brant E Isakson
Journal:  Pharmacol Rev       Date:  2014-03-26       Impact factor: 25.468

Review 6.  Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease.

Authors:  Antonio Rodríguez-Sinovas; Jose Antonio Sánchez; Laura Valls-Lacalle; Marta Consegal; Ignacio Ferreira-González
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

7.  Regulation of Cx37 channel and growth-suppressive properties by phosphorylation.

Authors:  Nicole L Jacobsen; Tasha K Pontifex; Hanjun Li; Joell L Solan; Paul D Lampe; Paul L Sorgen; Janis M Burt
Journal:  J Cell Sci       Date:  2017-08-17       Impact factor: 5.285

Review 8.  Role of phospholipid oxidation products in atherosclerosis.

Authors:  Sangderk Lee; Konstantin G Birukov; Casey E Romanoski; James R Springstead; Aldons J Lusis; Judith A Berliner
Journal:  Circ Res       Date:  2012-08-31       Impact factor: 17.367

Review 9.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

Review 10.  Gap junction and hemichannel-independent actions of connexins on cell and tissue functions--an update.

Authors:  Jade Z Zhou; Jean X Jiang
Journal:  FEBS Lett       Date:  2014-01-14       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.